CELGENE CORPORATION for CELGENE CORPORATION
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 20, 2016 | $570,000 | Replaced |
| 3rd Quarter - Amendment | Nov 15, 2016 | $820,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Corporate Tax Reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALAN EISENBERG | — |
| PATRICK GLIHA | — |
| MATTHEW SCHUMAKER | — |
Copyright/Patent/Trademark CPT
HR 9, "Innovation Act", provisions regarding patent reform. S 632, "STRONG Patents Act", provisions regarding patent reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALAN EISENBERG | — |
| PATRICK GLIHA | — |
| MATTHEW SCHUMAKER | — |
Health Issues HCR
HR 2841, "FAST Generic Act of 2015", regarding risk evaluation and mitigation strategy. HR 2739/S 1566, "Cancer Drug Coverage Parity Act", regarding all provisions. HR 1600, "Patients Access To Treatments Act", regarding all provisions. S 3056, "CREATES Act of 2016", provisions regarding REMS. Issues related to Medicare Part D/Part B, the Affordable Care Act, Regulation of Non-Biological Complex Drugs, TRICARE, & Step Therapy/Fail First.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALAN EISENBERG | — |
| PATRICK GLIHA | — |
| MATTHEW SCHUMAKER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.